BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37179150)

  • 21. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
    Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
    Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
    Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylation of subtelomeric repeat D4Z4 in peripheral blood leukocytes is associated with biochemical recurrence in localized prostate cancer patients.
    Han Y; Xu J; Kim J; Wu X; Gu J
    Carcinogenesis; 2017 Aug; 38(8):821-826. PubMed ID: 28854562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.
    Haldrup C; Mundbjerg K; Vestergaard EM; Lamy P; Wild P; Schulz WA; Arsov C; Visakorpi T; Borre M; Høyer S; Orntoft TF; Sørensen KD
    J Clin Oncol; 2013 Sep; 31(26):3250-8. PubMed ID: 23918943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant
    Bjerre MT; Strand SH; Nørgaard M; Kristensen H; Rasmussen AK; Mortensen MM; Fredsøe J; Mouritzen P; Ulhøi B; Ørntoft T; Borre M; Sørensen KD
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear Shape and Architecture in Benign Fields Predict Biochemical Recurrence in Prostate Cancer Patients Following Radical Prostatectomy: Preliminary Findings.
    Lee G; Veltri RW; Zhu G; Ali S; Epstein JI; Madabhushi A
    Eur Urol Focus; 2017 Oct; 3(4-5):457-466. PubMed ID: 28753763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
    Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
    Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer.
    Jiang Q; Xie M; He M; Yan F; Chen M; Xu S; Zhang X; Shen P
    Medicine (Baltimore); 2019 Jan; 98(1):e13820. PubMed ID: 30608394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
    Strand SH; Switnicki M; Moller M; Haldrup C; Storebjerg TM; Hedegaard J; Nordentoft I; Hoyer S; Borre M; Pedersen JS; Wild PJ; Park JY; Orntoft TF; Sorensen KD
    Oncotarget; 2017 Jan; 8(4):5774-5788. PubMed ID: 28052017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of RASSF1 promoter methylation in prostate cancer.
    Daniunaite K; Jarmalaite S; Kalinauskaite N; Petroska D; Laurinavicius A; Lazutka JR; Jankevicius F
    J Urol; 2014 Dec; 192(6):1849-55. PubMed ID: 24980613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular margin status after radical prostatectomy using glutathione S-transferase P1 (GSTP1) promoter hypermethylation.
    Witt JH; Friedrich M; Jandrig B; Porsch M; Baumunk D; Liehr UB; Wendler JJ; Schostak M
    BJU Int; 2022 Oct; 130(4):454-462. PubMed ID: 34657365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.
    Yu L; Toriseva M; Tuomala M; Seikkula H; Elo T; Tuomela J; Kallajoki M; Mirtti T; Taimen P; Boström PJ; Alanen K; Nurmi M; Nees M; Härkönen P
    Int J Cancer; 2016 Jul; 139(1):140-52. PubMed ID: 26891277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients.
    Savio AJ; Kamdar S; Jeyapala R; Olkhov-Mitsel E; Cuizon C; Finelli A; Zlotta AR; Toi A; Fleshner NE; van der Kwast T; Bapat B
    J Mol Diagn; 2020 Jan; 22(1):30-39. PubMed ID: 31605802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer.
    Litovkin K; Van Eynde A; Joniau S; Lerut E; Laenen A; Gevaert T; Gevaert O; Spahn M; Kneitz B; Gramme P; Helleputte T; Isebaert S; Haustermans K; Bollen M
    PLoS One; 2015; 10(6):e0130651. PubMed ID: 26086362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
    Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
    Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
    Bastian PJ; Ellinger J; Wellmann A; Wernert N; Heukamp LC; Müller SC; von Ruecker A
    Clin Cancer Res; 2005 Jun; 11(11):4097-106. PubMed ID: 15930345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
    Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
    Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of patients at risk for biochemical recurrence after radical prostatectomy with intra-operative frozen section.
    Tully KH; Schulmeyer M; Hanske J; Reike MJ; Brock M; Moritz R; Jütte H; Tannapfel A; von Bodman C; Noldus J; Palisaar RJ; Roghmann F
    BJU Int; 2021 Nov; 128(5):598-606. PubMed ID: 33961328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
    Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
    Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.